Waters (WAT) Q2 Revenue Jumps 9%

Waters (NYSE:WAT) reported better-than-expected Q2 2025 results, with GAAP revenue of $771 million, a 9% year-over-year increase, and non-GAAP EPS of $2.95, up 12%, both surpassing analyst estimates. This strong performance, driven by robust growth in pharmaceutical and industrial end-markets and significant expansion in recurring revenue streams, led management to raise its full-year 2025 guidance, now projecting 5.5% to 7.5% constant currency sales growth and non-GAAP EPS of $12.95 to $13.05, signaling confidence in sustained demand and operational execution despite some segment-specific pressures.

Analysis

Waters Corp. (WAT) delivered a robust financial performance in Q2 2025, exceeding analyst expectations and demonstrating strong operational execution. The company reported a 9% year-over-year increase in GAAP revenue to $771 million, surpassing consensus estimates by $22.34 million, while non-GAAP EPS grew 12% to $2.95. This outperformance was primarily fueled by an 11% sales increase in the critical pharmaceutical end-market and strong demand driven by an ongoing instrument replacement cycle. A key element of strength is the expansion of recurring revenue streams, which grew 12% to $462.9 million and now represent a stabilizing 60% of total company sales. This stability, combined with strong free cash flow growth of 10.6%, provided management the confidence to raise its full-year 2025 guidance to a range of 5.5% to 7.5% constant currency sales growth and non-GAAP EPS of $12.95 to $13.05. The positive outlook persists despite a 4% decline in the TA Instruments division and a potential $45 million gross impact from tariffs, which the company expects to mitigate to a net $10 million impact through inventory management and pricing adjustments without affecting its earnings forecast.

Key Decisions for Investors

• Given the strong Q2 earnings beat, raised full-year guidance, and successful mitigation of tariff impacts, the results reinforce a bullish thesis based on the company's resilient business model and strong execution.
• Investors should monitor the sustainability of the instrument replacement cycle and the growth trajectory of recurring revenues, as these are the primary drivers underpinning the upgraded financial outlook.
• It is prudent to watch for a turnaround in the underperforming TA Instruments segment and assess the company's continued ability to manage supply chain pressures and integrate acquisitions to protect future margins.